REVOLUTION

Manufacturer
Zoetis Inc.
Effective date
2024-12-11
Label type
PRESCRIPTION ANIMAL DRUG LABEL
Version
8
Source
full-release
Hydrated at
2026-06-01 02:43:58

Label at a glance#

ProductREVOLUTION
Active ingredientSELAMECTIN
Label structure22 sections

Dosage and administration

The recommended minimum dose is 2.7 mg selamectin per pound (6 mg/kg) of body weight. Administer the entire contents of a single dose tube (or two tubes used in combination for dogs weighing over 130 pounds) of Revolution topically in accordance with the following tables. Cats (lb) Package color mg per tube Potency (mg/mL) Administered volume (mL)  Up to 5  Mauve  15 mg  60  0.25  5.1–15  Blue  45 mg  60  0.75  15...

Storage and handling

Store below 30°C (86°F).

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

REVOLUTION® (selamectin)
Topical Parasiticide For Dogs and Cats

CAUTION

SPL UNCLASSIFIED SECTION

US Federal law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION

DESCRIPTION SECTION

Revolution (selamectin) Topical Parasiticide is available as a colorless to yellow, ready to use solution in single dose tubes for topical (dermal) treatment of dogs six weeks of age and older and cats eight weeks of age and older. The content of each tube is formulated to provide a minimum of 2.7 mg/lb (6 mg/kg) of body weight of selamectin. The chemical composition of selamectin is (5Z,25S)-25-cyclohexyl-4'-O-de(2,6-dideoxy-3-O-methyl-α-L-arabino-hexopyranosyl)-5-demethoxy-25-de(1-methylpropyl)-22,23-dihydro-5-hydroxyiminoavermectin A1a.

INDICATIONS

INDICATIONS & USAGE SECTION

Revolution is recommended for use in dogs six weeks of age or older and cats eight weeks of age and older for the following parasites and indications:

Dogs:

SPL UNCLASSIFIED SECTION

Revolution kills adult fleas and prevents flea eggs from hatching for one month and is indicated for the prevention and control of flea infestations (Ctenocephalides felis), prevention of heartworm disease caused by Dirofilaria immitis, and the treatment and control of ear mite (Otodectes cynotis) infestations. Revolution also is indicated for the treatment and control of sarcoptic mange (Sarcoptes scabiei) and for the control of tick infestations due to Dermacentor variabilis.

Cats:

SPL UNCLASSIFIED SECTION

Revolution kills adult fleas and prevents flea eggs from hatching for one month and is indicated for the prevention and control of flea infestations (Ctenocephalides felis), prevention of heartworm disease caused by Dirofilaria immitis, and the treatment and control of ear mite (Otodectes cynotis) infestations. Revolution is also indicated for the treatment and control of roundworm (Toxocara cati) and intestinal hookworm (Ancylostoma tubaeforme) infections in cats.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

The recommended minimum dose is 2.7 mg selamectin per pound (6 mg/kg) of body weight.

Administer the entire contents of a single dose tube (or two tubes used in combination for dogs weighing over 130 pounds) of Revolution topically in accordance with the following tables.

Cats (lb) Package color mg per tube Potency
(mg/mL)
Administered volume (mL)
 Up to 5 Mauve 15 mg 60 0.25
 5.1–15 Blue 45 mg 60 0.75
 15.1–22 Taupe 60 mg 60 1.0  

For cats over 22 lbs use the appropriate combination of tubes.

Dogs (lb) Package color mg per tube Potency
(mg/mL)
Administered volume (mL)
 Up to 5 Mauve 15 mg 60 0.25
 5.1–10 Purple 30 mg 120 0.25
 10.1–20 Brown 60 mg 120 0.5  
 20.1–40 Red 120 mg   120 1.0  
 40.1–85 Teal 240 mg   120 2.0  
 85.1–130 Plum 360 mg   120 3.0  

For dogs over 130 lbs use the appropriate combination of tubes.

Recommended for use in dogs 6 weeks of age and older and in cats 8 weeks of age and older.

A veterinarian or veterinary technician should demonstrate or instruct the pet owner regarding the appropriate technique for applying Revolution topically to dogs and cats prior to first use.

instruction diagraminstruction diagram

Firmly press the cap down to puncture the seal on the Revolution tube; a clicking sound will confirm that the cap has successfully punctured the seal. Remove the cap and check to ensure that the tip of the tube is open. To administer the product, part the hair on the back of the animal at the base of the neck in front of the shoulder blades until the skin is visible. Place the tip of the tube on the skin and squeeze the tube 3 or 4 times to empty its entire contents directly onto the skin in one spot. Keeping the tube squeezed, drag it away from the liquid and lift to remove. Check the tube to ensure that it is empty.

Do not massage the product into the skin. Due to alcohol content, do not apply to broken skin. Avoid contact between the product and fingers. Do not apply when the haircoat is wet. Bathing or shampooing the dog 2 or more hours after treatment will not reduce the effectiveness of Revolution against fleas or heartworm. Bathing or shampooing the cat 2 hours after treatment will not reduce the effectiveness of Revolution against fleas. Bathing or shampooing the cat 24 hours after treatment will not reduce the effectiveness of Revolution against heartworm. Stiff hair, clumping of hair, hair discoloration, or a slight powdery residue may be observed at the treatment site in some animals. These effects are temporary and do not affect the safety or effectiveness of the product. Discard empty tubes in your ordinary household refuse.

DOSAGE AND ADMINISTRATION continued

DOSAGE & ADMINISTRATION SECTION

Flea Control in Dogs and Cats

SPL UNCLASSIFIED SECTION

For the prevention and control of flea infestations, Revolution should be administered at monthly intervals throughout the flea season, starting one month before fleas become active. In controlled laboratory studies >98% of fleas were killed within 36 hours. Results of clinical field studies using Revolution monthly demonstrated >90% control of flea infestations within 30 days of the first dose. Dogs and cats treated with Revolution, including those with pre-existing flea allergy dermatitis, showed improvement in clinical signs associated with fleas as a direct result of eliminating the fleas from the animals and their environment.

If the dog or cat is already infested with fleas when the first dose of Revolution is administered, adult fleas on the animal are killed and no viable fleas hatch from eggs after the first administration. However, an environmental infestation of fleas may persist for a short time after beginning treatment with Revolution because of the emergence of adult fleas from pupae.

Heartworm Prevention in Dogs and Cats

SPL UNCLASSIFIED SECTION

For the prevention of heartworm disease, Revolution must be administered on a monthly basis. Revolution may be administered year-round or at least within one month after the animal's first exposure to mosquitoes and monthly thereafter until the end of the mosquito season. The final dose must be given within one month after the last exposure to mosquitoes. If a dose is missed and a monthly interval between dosing is exceeded then immediate administration of Revolution and resumption of monthly dosing will minimize the opportunity for the development of adult heartworms. When replacing another heartworm preventive product in a heartworm disease prevention program, the first dose of Revolution must be given within a month of the last dose of the former medication.

Selamectin, the active ingredient in Revolution, is a macrocyclic lactone compound. These compounds effectively prevent the development of adult heartworms when administered to dogs and cats within one month of exposure to infective (L3) Dirofilaria immitis larvae. Efficacy of macrocyclic lactones decreases below 100% in dogs, however, if first administered >2 months after exposure to infective larvae. Thus, in heartworm endemic regions, delaying initiation of heartworm prevention using Revolution beyond 2 months of first exposure to infective larvae (e.g., starting puppies and kittens at >8 weeks of age), or gaps of >2 months in the administration of Revolution during periods of heartworm transmission, increases the risk of the animal acquiring heartworms. Animals with unknown heartworm history that test negative for heartworms prior to the initiation of Revolution may be harboring pre-patent infections at the time Revolution was started. Testing such animals 3–4 months after initiation of Revolution would be necessary to confirm their negative heartworm status.

At the discretion of the veterinarian, cats ≥6 months of age may be tested to determine the presence of existing heartworm infections before beginning treatment with Revolution. Cats already infected with adult heartworms can be given Revolution monthly to prevent further infections.

Ear Mite Treatment in Dogs and Cats

SPL UNCLASSIFIED SECTION

For the treatment of ear mite (O. cynotis) infestations in dogs and cats, Revolution should be administered once as a single topical dose. A second monthly dose may be required in some dogs. Monthly use of Revolution will control any subsequent ear mite infestations. In the clinical field trials ears were not cleaned, and many animals still had debris in their ears after the second dose. Cleansing of the infested ears is recommended to remove the debris.

Sarcoptic Mange Treatment in Dogs

SPL UNCLASSIFIED SECTION

For the treatment of sarcoptic mange (S. scabiei) in dogs, Revolution should be administered once as a single topical dose. A second monthly dose may be required in some dogs. Monthly use of Revolution will control any subsequent sarcoptic mange mite infestations. Because of the difficulty in finding sarcoptic mange mites on skin scrapings, effectiveness assessments also were based on resolution of clinical signs. Resolution of the pruritus associated with the mite infestations was observed in approximately 50% of the dogs 30 days after the first treatment and in approximately 90% of the dogs 30 days after the second monthly treatment.

Tick Control in Dogs

SPL UNCLASSIFIED SECTION

For the control of tick (Dermacentor variabilis) infestations in dogs, Revolution should be administered on a monthly basis. In heavy tick infestations, complete efficacy may not be achieved after the first dose. In these cases, one additional dose may be administered two weeks after the previous dose, with monthly dosing continued thereafter.

Nematode Treatment in Cats

SPL UNCLASSIFIED SECTION

For the treatment and control of intestinal hookworm (A. tubaeforme) and roundworm (T. cati) infections, Revolution should be applied once as a single topical dose.

WARNINGS

WARNINGS SECTION

User Safety Warnings
Not for human use. Keep out of reach of children.
In humans, Revolution may be irritating to skin and eyes.


Reactions such as hives, itching and skin redness have been reported in humans. Individuals with known hypersensitivity to Revolution should use the product with caution or consult a health care professional. Revolution contains isopropyl alcohol and the preservative butylated hydroxytoluene (BHT).

Wash hands after use and wash off any product in contact with the skin immediately with soap and water.

If contact with eyes occurs, then flush eyes copiously with water; if wearing contact lenses, rinse the eyes first then remove contact lenses and continue to rinse for 5-10 minutes and seek medical attention.

In case of ingestion by a human, contact a physician immediately.

The safety data sheet (SDS) provides more detailed occupational safety information. To obtain a SDS contact Zoetis at 1-888-963-8471 or www.zoetisus.com.

Flammable - Keep away from heat, sparks, open flames or other sources of ignition.

Animal Safety Warnings
Do not use in sick, debilitated or underweight animals (
see TARGET ANIMAL SAFETY).

PRECAUTIONS

PRECAUTIONS SECTION

Prior to administration of Revolution, dogs should be tested for existing heartworm infections. At the discretion of the veterinarian, infected dogs should be treated to remove adult heartworms. Revolution is not effective against adult D. immitis and, while the number of circulating microfilariae may decrease following treatment, Revolution is not effective for microfilariae clearance.

Hypersensitivity reactions have not been observed in dogs with patent heartworm infections administered Revolution (see TARGET ANIMAL SAFETY).

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Pre-approval clinical trials:

SPL UNCLASSIFIED SECTION

Following treatment with Revolution, transient localized alopecia with or without inflammation at or near the site of application was observed in approximately 1% of 691 treated cats. Other signs observed (≤0.5% of 1743 treated cats and dogs) included vomiting, loose stool or diarrhea with or without blood, anorexia, lethargy, salivation, tachypnea, and muscle tremors.

Post-approval experience (2021):

SPL UNCLASSIFIED SECTION

The following adverse events are based on post-approval adverse drug experience reporting for Revolution. Not all adverse events are reported to FDA/CVM. It is not always possible to reliably estimate the adverse event frequency or establish a causal relationship to product exposure using this data.

The following adverse events reported for dogs are listed in decreasing order of reporting frequency:
Lethargy, vomiting, diarrhea, anorexia, generalized pruritus, seizures, application site reactions (including alopecia, lesions, erythema, pruritus, and inflammation), tremors, ataxia, death, and dermatitis.

The following adverse events reported for cats are listed in decreasing order of reporting frequency:
Application site reactions (including alopecia, lesions, erythema, pruritus, inflammation, vesicles, blisters, and excoriations), lethargy, anorexia, vomiting, death, generalized pruritus, diarrhea, ataxia, fever, generalized alopecia, tremors, hypersalivation, dermatitis, and seizures.

CONTACT INFORMATION

SPL UNCLASSIFIED SECTION

Contact Zoetis at 1-888-963-8471 or www.zoetis.com. To report suspected adverse drug experiences, contact Zoetis at 1-888-963-8471. For additional information about reporting adverse drug experiences for animal drugs, contact FDA at 1-888-FDA-VETS or www.fda.gov/reportanimalae.

TARGET ANIMAL SAFETY

SPL UNCLASSIFIED SECTION

Revolution has been tested safe in over 100 different pure and mixed breeds of healthy dogs and over 15 different pure and mixed breeds of healthy cats, including pregnant and lactating females, breeding males and females, puppies six weeks of age and older, kittens eight weeks of age and older, and avermectin-sensitive collies. A kitten, estimated to be 5–6 weeks old (0.3 kg), died 8 1⁄2 hours after receiving a single treatment of Revolution at the recommended dosage. The kitten displayed clinical signs which included muscle spasms, salivation and neurological signs. The kitten was a stray with an unknown history and was malnourished and underweight (see WARNINGS).

DOGS:

SPL UNCLASSIFIED SECTION

In safety studies, Revolution was administered at 1, 3, 5, and 10 times the recommended dose to six-week-old puppies, and no adverse reactions were observed. The safety of Revolution administered orally also was tested in case of accidental oral ingestion. Oral administration of Revolution at the recommended topical dose in 5- to 8-month-old beagles did not cause any adverse reactions. In a pre-clinical study selamectin was dosed orally to ivermectin-sensitive collies. Oral administration of 2.5, 10, and 15 mg/kg in this dose escalating study did not cause any adverse reactions; however, eight hours after receiving 5 mg/kg orally, one avermectin-sensitive collie became ataxic for several hours, but did not show any other adverse reactions after receiving subsequent doses of 10 and 15 mg/kg orally. In a topical safety study conducted with avermectin-sensitive collies at 1, 3 and 5 times the recommended dose of Revolution, salivation was observed in all treatment groups, including the vehicle control. Revolution also was administered at 3 times the recommended dose to heartworm infected dogs, and no adverse effects were observed.

CATS:

SPL UNCLASSIFIED SECTION

In safety studies, Revolution was applied at 1, 3, 5, and 10 times the recommended dose to six-week-old kittens. No adverse reactions were observed. The safety of Revolution administered orally also was tested in case of accidental oral ingestion. Oral administration of the recommended topical dose of Revolution to cats caused salivation and intermittent vomiting. Revolution also was applied at 4 times the recommended dose to patent heartworm infected cats, and no adverse reactions were observed.

In well-controlled clinical studies, Revolution was used safely in animals receiving other frequently used veterinary products such as vaccines, anthelmintics, antiparasitics, antibiotics, steroids, collars, shampoos and dips.

STORAGE CONDITIONS

STORAGE AND HANDLING SECTION

Store below 30°C (86°F).

HOW SUPPLIED

HOW SUPPLIED SECTION

Available in eight separate dose strengths for dogs and cats of different weights (see DOSAGE).  Revolution for puppies and kittens is available in cartons containing 3 single dose tubes. Revolution for cats and dogs is available in cartons containing 3 or 6 single dose tubes.

SPL UNCLASSIFIED SECTION

Approved by FDA under NADA # 141-152
Revised: July 2024

zoetis

Manufactured and Distributed by:
Zoetis Inc.
Kalamazoo, MI 49007
Product of the United Kingdom

40048985

PRINCIPAL DISPLAY PANEL - 15 mg Tube Carton

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

15 mg Tube Carton15 mg Tube Carton

PRINCIPAL DISPLAY PANEL - 30 mg Tube Carton

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

30 mg Tube Carton30 mg Tube Carton

PRINCIPAL DISPLAY PANEL - 45 mg Tube Carton

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

45 mg Tube Carton45 mg Tube Carton

PRINCIPAL DISPLAY PANEL - 60 mg (1 mL) Tube Carton

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

60 mg (1 mL) Tube Carton60 mg (1 mL) Tube Carton

PRINCIPAL DISPLAY PANEL - 60 mg (0.5 mL) Tube Carton

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

60 mg (0.5 mL) Tube Carton60 mg (0.5 mL) Tube Carton

PRINCIPAL DISPLAY PANEL - 120 mg Tube Carton

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

120 mg Tube Carton120 mg Tube Carton

PRINCIPAL DISPLAY PANEL - 240 mg Tube Carton

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

240 mg Tube Carton240 mg Tube Carton

PRINCIPAL DISPLAY PANEL - 360 mg Tube Carton

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

360 mg Tube Carton360 mg Tube Carton

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
1044276revolution 120 MG/ML Topical SolutionPSN8
1044281revolution 60 MG/ML Topical SolutionPSN8
1044272selamectin 120 MG in 1 ML Topical SolutionPSN8
1044279selamectin 60 MG in 1 ML Topical SolutionPSN8
1044276selamectin 120 MG/ML Topical Solution [Revolution]SBD8
1044281selamectin 60 MG/ML Topical Solution [Revolution]SBD8
1044272selamectin 120 MG/ML Topical SolutionSCD8
1044279selamectin 60 MG/ML Topical SolutionSCD8
1044276Revolution 120 MG/ML Topical SolutionSY8
1044281Revolution 60 MG/ML Topical SolutionSY8
1044272selamectin 120 MG per 1 ML Topical SolutionSY8
1044279selamectin 60 MG per 1 ML Topical SolutionSY8

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
54771-9660-1REVOLUTION0.75 mL in 1 TUBESOLUTION0.758
54771-9660-1REVOLUTION3 in 1 CARTONSOLUTION38
54771-9660-2REVOLUTION0.75 mL in 1 TUBESOLUTION0.758
54771-9660-2REVOLUTION6 in 1 CARTONSOLUTION68
54771-9661-1REVOLUTION3 in 1 CARTONSOLUTION38
54771-9661-1REVOLUTION0.25 mL in 1 TUBESOLUTION0.258
54771-9662-1REVOLUTION3 in 1 CARTONSOLUTION38
54771-9662-1REVOLUTION0.25 mL in 1 TUBESOLUTION0.258
54771-9662-2REVOLUTION0.25 mL in 1 TUBESOLUTION0.258
54771-9662-2REVOLUTION6 in 1 CARTONSOLUTION68
54771-9663-1REVOLUTION0.5 mL in 1 TUBESOLUTION0.58
54771-9663-1REVOLUTION3 in 1 CARTONSOLUTION38
54771-9663-2REVOLUTION0.5 mL in 1 TUBESOLUTION0.58
54771-9663-2REVOLUTION6 in 1 CARTONSOLUTION68
54771-9664-1REVOLUTION1 mL in 1 TUBESOLUTION18
54771-9664-1REVOLUTION3 in 1 CARTONSOLUTION38
54771-9664-2REVOLUTION6 in 1 CARTONSOLUTION68
54771-9664-2REVOLUTION1 mL in 1 TUBESOLUTION18
54771-9665-1REVOLUTION3 in 1 CARTONSOLUTION38
54771-9665-1REVOLUTION2 mL in 1 TUBESOLUTION28
54771-9665-2REVOLUTION2 mL in 1 TUBESOLUTION28
54771-9665-2REVOLUTION6 in 1 CARTONSOLUTION68
54771-9667-1REVOLUTION3 mL in 1 TUBESOLUTION38
54771-9667-1REVOLUTION3 in 1 CARTONSOLUTION38
54771-9667-2REVOLUTION6 in 1 CARTONSOLUTION68
54771-9667-2REVOLUTION3 mL in 1 TUBESOLUTION38
54771-9668-1REVOLUTION3 in 1 CARTONSOLUTION38
54771-9668-1REVOLUTION1 mL in 1 TUBESOLUTION18
54771-9668-2REVOLUTION1 mL in 1 TUBESOLUTION18
54771-9668-2REVOLUTION6 in 1 CARTONSOLUTION68

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
54771-9660REVOLUTION (SELAMECTIN) SOLUTION [ZOETIS INC.]84 package rows20241213_8032a1ae-d192-4514-80f1-9a3b50dc2155.zip
54771-9661REVOLUTION (SELAMECTIN) SOLUTION [ZOETIS INC.]82 package rows20241213_8032a1ae-d192-4514-80f1-9a3b50dc2155.zip
54771-9662REVOLUTION (SELAMECTIN) SOLUTION [ZOETIS INC.]84 package rows20241213_8032a1ae-d192-4514-80f1-9a3b50dc2155.zip
54771-9663REVOLUTION (SELAMECTIN) SOLUTION [ZOETIS INC.]84 package rows20241213_8032a1ae-d192-4514-80f1-9a3b50dc2155.zip
54771-9664REVOLUTION (SELAMECTIN) SOLUTION [ZOETIS INC.]84 package rows20241213_8032a1ae-d192-4514-80f1-9a3b50dc2155.zip
54771-9665REVOLUTION (SELAMECTIN) SOLUTION [ZOETIS INC.]84 package rows20241213_8032a1ae-d192-4514-80f1-9a3b50dc2155.zip
54771-9667REVOLUTION (SELAMECTIN) SOLUTION [ZOETIS INC.]84 package rows20241213_8032a1ae-d192-4514-80f1-9a3b50dc2155.zip
54771-9668REVOLUTION (SELAMECTIN) SOLUTION [ZOETIS INC.]84 package rows20241213_8032a1ae-d192-4514-80f1-9a3b50dc2155.zip

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
selamectinACTIVE INGREDIENTA2669OWX9N1
selamectinACTIVE MOIETYA2669OWX9N1
butylated hydroxytolueneINACTIVE INGREDIENT1P9D0Z171K1
isopropyl alcoholINACTIVE INGREDIENTND2M4163021

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 4 matching rows.

NDC Codes#

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 24 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 1 · 41 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
butylated hydroxytolueneBUTYLATED HYDROXYTOLUENE1P9D0Z171KTABLET / SUBLINGUAL0.13 mgExact identifier — unii candidate
32 equally ranked IID candidates
butylated hydroxytolueneBUTYLATED HYDROXYTOLUENE1P9D0Z171KTABLET, ORALLY DISINTEGRATING / ORAL1 mgExact identifier — unii candidate
32 equally ranked IID candidates
isopropyl alcoholISOPROPYL ALCOHOLND2M416302SWAB / TOPICAL43.9 %w/wExact identifier — unii candidate
9 equally ranked IID candidates
isopropyl alcoholISOPROPYL ALCOHOLND2M416302GEL, METERED / TOPICAL525 mgExact identifier — unii candidate
9 equally ranked IID candidates
butylated hydroxytolueneBUTYLATED HYDROXYTOLUENE1P9D0Z171KGUM, CHEWING / BUCCAL5 mgExact identifier — unii candidate
32 equally ranked IID candidates
butylated hydroxytolueneBUTYLATED HYDROXYTOLUENE1P9D0Z171KTABLET / ORAL3 mgExact identifier — unii candidate
32 equally ranked IID candidates
butylated hydroxytolueneBUTYLATED HYDROXYTOLUENE1P9D0Z171KINJECTION / INTRAVENOUSNAExact identifier — unii candidate
32 equally ranked IID candidates
butylated hydroxytolueneBUTYLATED HYDROXYTOLUENE1P9D0Z171KFILM, SOLUBLE / ORAL0.06 mgExact identifier — unii candidate
32 equally ranked IID candidates
butylated hydroxytolueneBUTYLATED HYDROXYTOLUENE1P9D0Z171KGEL, METERED / TOPICAL4 mgExact identifier — unii candidate
32 equally ranked IID candidates
butylated hydroxytolueneBUTYLATED HYDROXYTOLUENE1P9D0Z171KCAPSULE / ORAL3 mgExact identifier — unii candidate
32 equally ranked IID candidates
isopropyl alcoholISOPROPYL ALCOHOLND2M416302LOTION, AUGMENTED / TOPICAL2070 mgExact identifier — unii candidate
9 equally ranked IID candidates
butylated hydroxytolueneBUTYLATED HYDROXYTOLUENE1P9D0Z171KSUPPOSITORY / VAGINALNAExact identifier — unii candidate
32 equally ranked IID candidates
butylated hydroxytolueneBUTYLATED HYDROXYTOLUENE1P9D0Z171KCAPSULE, EXTENDED RELEASE / ORAL0.03 mgExact identifier — unii candidate
32 equally ranked IID candidates
isopropyl alcoholISOPROPYL ALCOHOLND2M416302SOLUTION / TOPICAL40 %w/vExact identifier — unii candidate
9 equally ranked IID candidates
isopropyl alcoholISOPROPYL ALCOHOLND2M416302OIL / AURICULAR (OTIC)6 mgExact identifier — unii candidate
9 equally ranked IID candidates
butylated hydroxytolueneBUTYLATED HYDROXYTOLUENE1P9D0Z171KSUPPOSITORY / RECTAL1 mgExact identifier — unii candidate
32 equally ranked IID candidates
butylated hydroxytolueneBUTYLATED HYDROXYTOLUENE1P9D0Z171KLOTION / TOPICAL1000 mgExact identifier — unii candidate
32 equally ranked IID candidates
butylated hydroxytolueneBUTYLATED HYDROXYTOLUENE1P9D0Z171KSOLUTION / ORAL14 mgExact identifier — unii candidate
32 equally ranked IID candidates
butylated hydroxytolueneBUTYLATED HYDROXYTOLUENE1P9D0Z171KCREAM, AUGMENTED / TOPICAL0.2 %w/wExact identifier — unii candidate
32 equally ranked IID candidates
butylated hydroxytolueneBUTYLATED HYDROXYTOLUENE1P9D0Z171KCREAM / VAGINAL0.05 %w/wExact identifier — unii candidate
32 equally ranked IID candidates
butylated hydroxytolueneBUTYLATED HYDROXYTOLUENE1P9D0Z171KAEROSOL, FOAM / TOPICAL4 mgExact identifier — unii candidate
32 equally ranked IID candidates
butylated hydroxytolueneBUTYLATED HYDROXYTOLUENE1P9D0Z171KCAPSULE, LIQUID FILLED / ORAL0.1 mgExact identifier — unii candidate
32 equally ranked IID candidates
isopropyl alcoholISOPROPYL ALCOHOLND2M416302OIL / TOPICAL72 mgExact identifier — unii candidate
9 equally ranked IID candidates
butylated hydroxytolueneBUTYLATED HYDROXYTOLUENE1P9D0Z171KSOLUTION, CONCENTRATE / ORAL0.1 mg/1mlExact identifier — unii candidate
32 equally ranked IID candidates
butylated hydroxytolueneBUTYLATED HYDROXYTOLUENE1P9D0Z171KINJECTION, POWDER, FOR SOLUTION / INTRAVENOUSNAExact identifier — unii candidate
32 equally ranked IID candidates
butylated hydroxytolueneBUTYLATED HYDROXYTOLUENE1P9D0Z171KTABLET, EXTENDED RELEASE / ORAL1 mgExact identifier — unii candidate
32 equally ranked IID candidates
butylated hydroxytolueneBUTYLATED HYDROXYTOLUENE1P9D0Z171KTABLET, FOR SUSPENSION / ORAL0.1 mgExact identifier — unii candidate
32 equally ranked IID candidates
butylated hydroxytolueneBUTYLATED HYDROXYTOLUENE1P9D0Z171KSOLUTION / TOPICAL3 mgExact identifier — unii candidate
32 equally ranked IID candidates
butylated hydroxytolueneBUTYLATED HYDROXYTOLUENE1P9D0Z171KINJECTION, SOLUTION / INTRAVENOUSNAExact identifier — unii candidate
32 equally ranked IID candidates
butylated hydroxytolueneBUTYLATED HYDROXYTOLUENE1P9D0Z171KSHAMPOO / TOPICAL0.1 %w/wExact identifier — unii candidate
32 equally ranked IID candidates
isopropyl alcoholISOPROPYL ALCOHOLND2M416302TABLET, EXTENDED RELEASE / ORALNAExact identifier — unii candidate
9 equally ranked IID candidates
butylated hydroxytolueneBUTYLATED HYDROXYTOLUENE1P9D0Z171KSPRAY / TOPICAL3 mgExact identifier — unii candidate
32 equally ranked IID candidates
isopropyl alcoholISOPROPYL ALCOHOLND2M416302GEL / TOPICAL75 mgExact identifier — unii candidate
9 equally ranked IID candidates
butylated hydroxytolueneBUTYLATED HYDROXYTOLUENE1P9D0Z171KINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS0.02 mgExact identifier — unii candidate
32 equally ranked IID candidates
butylated hydroxytolueneBUTYLATED HYDROXYTOLUENE1P9D0Z171KSOAP / TOPICAL0.02 %w/wExact identifier — unii candidate
32 equally ranked IID candidates
butylated hydroxytolueneBUTYLATED HYDROXYTOLUENE1P9D0Z171KGEL / TOPICAL8 mgExact identifier — unii candidate
32 equally ranked IID candidates
butylated hydroxytolueneBUTYLATED HYDROXYTOLUENE1P9D0Z171KSPRAY, METERED / NASAL0.1 mg/1mlExact identifier — unii candidate
32 equally ranked IID candidates
butylated hydroxytolueneBUTYLATED HYDROXYTOLUENE1P9D0Z171KSWAB / TOPICAL0.5 %w/wExact identifier — unii candidate
32 equally ranked IID candidates
isopropyl alcoholISOPROPYL ALCOHOLND2M416302SPONGE / TOPICAL4 %w/wExact identifier — unii candidate
9 equally ranked IID candidates
butylated hydroxytolueneBUTYLATED HYDROXYTOLUENE1P9D0Z171KOINTMENT / TOPICAL57 mgExact identifier — unii candidate
32 equally ranked IID candidates
butylated hydroxytolueneBUTYLATED HYDROXYTOLUENE1P9D0Z171KCREAM / TOPICAL6 mgExact identifier — unii candidate
32 equally ranked IID candidates

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.